Original Article. Ting-Chi Yeh
|
|
- Jack Miller
- 5 years ago
- Views:
Transcription
1 Treatment of Childhood Acute Lymphoblastic Leukemia With Delayed First Intrathecal Therapy and Omission of Prophylactic Cranial Irradiation: Results of the TPOG-ALL-2002 Study Ting-Chi Yeh 1 ; Der-Cherng Liang* 1 ; Jen-Yin Hou 1 ; Tang-Her Jaing 2 ; Dong-Tsamn Lin 3 ; Chao-Ping Yang 2 ; Ching-Tien Peng 4,5 ; Iou-Jih Hung 2 ; Kai-Hsin Lin 3 ; Chih-Cheng Hsiao 6 ; Shiann-Tarng Jou 3 ; Shyh-Shin Chiou 7 ; Jiann-Shiuh Chen 8 ; Shih-Chung Wang 9 ; Te-Kau Chang 10 ; Kang-Hsi Wu 4 ; Jiunn-Ming Sheen 6 ; Hsiu-Ju Yen 11 ; Shih-Hsiang Chen 2 ; Meng-Yao Lu 3 ; Meng-Ju Li 3,12 ; Tai-Tsung Chang 13 ; Ting-Huan Huang 1 ; Yu-Hsiang Chang 14 ; Shu-Huey Chen 15 ; Yung-Li Yang 3 ; Hsiu-Hao Chang 3 ; Bow-Wen Chen 16 ; Pei-Chin Lin 7 ; Chao-Neng Cheng 8 ; Yu-Hua Chao 17 ; Shang-Hsien Yang 18 ; Yu-Mei Y. Chao 19 ; and Hsi-Che Liu 1 BACKGROUND: To eliminate cranial irradiation (CrRT) related sequelae and to minimize the adverse impact of traumatic lumbar puncture (TLP) with blasts, the Taiwan Pediatric Oncology Group (TPOG) introduced a modified central nervous system (CNS) directed regimen characterized by delayed triple intrathecal therapy (TIT) and the omission of CrRT for all children with newly diagnosed acute lymphoblastic leukemia (ALL). METHODS: This study compared the treatment outcomes of patients overall and patients with a non CNS-1 status (CNS-2, CNS-3, or TLP with blasts) in 2 treatment eras, one before and another after the revision of the TPOG-ALL-2002 protocol by the introduction of the modification (era 1 [ ] with CrRT and era 2 [ ] with delayed first TIT and no CrRT). RESULTS: There were no statistically significant differences in major outcomes between the 903 patients treated in era 1 and the 444 patients treated in era 2: the 5-year event-free survival (EFS) rates were 75.7% ± 1.4% and 72.1% ± 2.4%, respectively (P =.260), and the cumulative risks of isolated CNS relapse were 4.0% ± 0.7% and 4.1% ± 1.0%, respectively (P =.960). There were also no differences between non CNS-1 patients treated in era 1 (n = 76) and era 2 (n =28): the 5-year EFS rates were 52.3% ± 5.8% and 62.9% ± 9.4%, respectively (P =.199), and the cumulative risks of isolated CNS relapse were 6.3% ± 3.1% and 3.6% ± 3.5%, respectively (P =.639). Notably, TLP with blasts was completely eliminated after the first TIT was delayed in era 2. CONCLUSIONS: The delay of the first TIT until the clearance of circulating blasts and the total omission of CrRT did not compromise survival or CNS control in patients with childhood ALL, including those with a non CNS-1 status. Cancer 2018;000: American Cancer Society. KEYWORDS: acute lymphoblastic leukemia, central nervous system, children, cranial irradiation, intrathecal chemotherapy INTRODUCTION Cranial irradiation (CrRT), once a standard central nervous system (CNS) directed therapy for childhood acute lymphoblastic leukemia (ALL), has increasingly been omitted from protocols because of its many recognized complications, including second cancers (especially brain tumors), a decreased intelligence quotient, cognitive deficits, and Corresponding author: Hsi-Che Liu, Division of Pediatric Hematology-Oncology, Mackay Memorial Hospital, No. 92, Section 2, Chung-San North Road, Taipei 10449, Taiwan; hsiche@mmh.org.tw 1 Division of Pediatric Hematology-Oncology, Mackay Memorial Hospital and Mackay Medical College, Taipei, Taiwan; 2 Department of Hematology-Oncology, Chang Gung Children s Hospital Linkou and Chang Gung University, Taoyuan, Taiwan; 3 Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan; 4 Division of Pediatric Hematology and Oncology, China Medical University Children s Hospital, Taichung, Taiwan; 5 Department of Biotechnology, Asia University, Taichung, Taiwan; 6 Department of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan; 7 Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 8 Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan; 9 Department of Pediatrics, Changhua Christian Hospital, Changhua, Taiwan; 10 Department of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan; 11 Department of Pediatrics, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan; 12 Department of Pediatrics, National Taiwan University Hospital Hsin Chu Branch, Hsinchu, Taiwan; 13 Department of Pediatrics, Chia-Yi Christian Hospital, Chiayi, Taiwan; 14 Department of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 15 Department of Pediatrics, Taipei Medical University Shuang Ho Hospital, Taipei, Taiwan; 16 Division of Pediatric Hematology and Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan; 17 Department of Pediatrics, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, Taiwan; 18 Department of Pediatrics, Buddhist Tzu Chi General Hospital, Hualien, Taiwan; 19 Childhood Cancer Foundation, Taipei, Taiwan *Deceased. Additional supporting information may be found in the online version of this article. We thank the data managers of the Biostatistical Center of the Childhood Cancer Foundation (Taiwan) for their assistance and Fang-Ju Sun (Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan) for assistance with the statistical analysis. We dedicate this article to the memory of Professor Der-Cherng Liang. DOI: /cncr.31758, Received: May 9, 2018; Revised: June 25, 2018; Accepted: July 6, 2018, Published online Month 00, 2018 in Wiley Online Library (wileyonlinelibrary.com) 1
2 endocrinopathy. 1 4 The most recent protocols for ALL limit the use of prophylactic CrRT to 0% to 33% of childhood ALL patients. 5,6 To abolish CrRT-related sequelae and minimize the adverse prognostic impact of traumatic lumbar puncture (TLP) with blasts, beginning in 1999, we conducted a single-institution study at Mackay Memorial Hospital to modify CNS-directed therapy with delayed triple intrathecal therapy (TIT) upon the clearance of circulating blasts or up to 10 days after multidrug induction and with the omission of CrRT for all risk groups with newly diagnosed ALL. 7 We reasoned that the delayed intrathecal therapy approach would reduce the proportion of patients having TLP with blasts, an adverse risk feature associated with poor event-free survival (EFS) and an increased risk of CNS relapse. 8 Among the 152 patients treated in the Mackay study, the estimated 5-year EFS and overall survival (OS) rates (presented as mean ± standard error) were 84.2% ± 3.0% and 90.6% ± 2.4%, respectively. There were no isolated CNS relapses, and only 2 patients had combined CNS relapses. The 7-year cumulative risk of any CNS relapse was 1.4% ± 1.0%. Hence, the Mackay study improved CNS control and survival without compromising the systemic control of leukemia, and it enhanced the quality of life of patients by omitting the use of prophylactic CrRT. 7 These results led us to revise the protocol of a multi-institutional study (Taiwan Pediatric Oncology Group Acute Lymphoblastic Leukemia 2002 [TPOG-ALL-2002]) to add this modified CNS treatment in January A comparison of overall treatment outcomes between patients treated in the early era with prophylactic CrRT and patients treated in the recent era with delayed intrathecal therapy and the omission of prophylactic CrRT has been previously reported. 9 We now provide additional analysis with longer follow-up and show that the modified CNS treatment also did not compromise the outcomes of patients with a non CNS-1 status in this groupwide study. MATERIALS AND METHODS Patients From 2002 to 2012, all children in Taiwan with newly diagnosed ALL (0-18 years old) were enrolled in the TPOG-ALL-2002 study. Those with B-precursor ALL were stratified into standard-risk (SR), high-risk (HR), and very high-risk (VHR) groups according to their age, leukocyte count, cytogenetics, and molecular analysis at diagnosis. Patients with T-cell ALL were considered part of the VHR group. Details of the risk stratification and treatment regimens were previously published 7,9,10 (see the supporting information). All protocols were approved by the institutional review boards of the participating institutions. Written informed consent was obtained from the patients, parents, or guardians. CNS-Directed Therapy The CNS status was defined as follows: CNS-1, no blasts in a nontraumatic sample; CNS-2, fewer than 5 leukocytes per microliter with blasts in a nontraumatic sample; CNS-3, 5 or more leukocytes per microliter with blasts in a nontraumatic sample or the presence of cranial nerve palsy; and TLP, 10 or more erythrocytes per microliter with or without blasts. 11 Since January 2009, diagnostic lumbar puncture and the first TIT injection were not performed until blasts were no longer detectable in peripheral blood, but they were performed no later than 10 days after the initiation of induction therapy. Exceptions were made for patients who presented with cranial nerve palsy or other evidence of CNS disease; in these cases, lumbar puncture and the first TIT dose were administered on the day of diagnosis. SR patients with cranial nerve palsy, detectable blasts in peripheral blood on day 8, or a CNS-3 status were classified as HR. SR patients with CNS-1 received 14 doses of TIT, whereas those with CNS-2 or TLP with blasts received 2 additional TIT induction therapy and another 3 during maintenance therapy for a total of 19 doses. In the HR group, those with CNS-1 were given 17 doses of TIT; this escalated to 25 doses for those with CNS-2, CNS-3, or TLP with blasts, including 2 doses during induction and 6 during maintenance therapy. Before 2009, 18 Gy of CrRT was introduced prophylactically to VHR patients with a CNS-1 status at the beginning of maintenance therapy, and this was coupled with 5 concomitant TIT treatments; those younger than 2 years were excluded and were given TIT instead. VHR patients with CNS-2, CNS-3, or TLP with blasts at diagnosis received TIT weekly during induction until cerebrospinal fluid (CSF) remission was achieved and then once every 4 weeks during maintenance therapy before 24 Gy of CrRT. Among SR and HR patients, only those with refractory CNS leukemia at diagnosis (i.e., a failure to clear CSF blasts after 3 consecutive TIT treatments) received 24 Gy of CrRT with 5 concomitant TIT treatments at 1 year of remission. Since 2009, all patients have been treated with TIT alone without CrRT, and the doses and schedule of TIT have remained the same. The doses and timing of CNS-directed therapy by risk 2
3 Treatment Outcomes of Childhood ALL/Yeh et al TABLE 1. CNS-Directed Therapy According to Risk Group and CNS Status in 2 Treatment Eras CrRT TIT CNS-1: 14 doses Treatment Era SR HR VHR SR HR VHR Only for refractory CNS leukemia at diagnosis and CNS relapse CNS-2, TLP with blasts: 19 doses; +2 induction and 3 maintenance CNS-1: 17 doses CNS-2/3, TLP with blasts: 25 doses; +2 induction and 6 maintenance At an age 2 y: 18 Gy plus 5 TIT treatments in 1st wk of maintenance; 24 Gy plus 5 TIT treatments for CNS-2/3 or TLP with blasts CNS-1: 10 doses before CrRT; if an age < 2 y at diagnosis, 10 doses and then every 8 wk before CrRT CNS-2/3, TLP with blasts: every week until CSF clear and then every 4 wk before CrRT; no TIT after CrRT Omission for all risk groups CNS-1: 14 doses CNS-1: 17 doses CNS-1: 19 doses CNS-2, TLP with blasts: 19 doses; +2 induction and 3 maintenance CNS-2/3, TLP with blasts: 25 doses; +2 induction and 6 maintenance CNS-2/3, TLP with blasts: every week until CSF clear; every 4 wk during maintenance Abbreviations: CNS, central nervous system; CrRT, cranial irradiation; CSF, cerebrospinal fluid; HR, high risk; SR, standard risk; TIT, triple intrathecal therapy; TLP, traumatic lumbar puncture; VHR, very high risk. CNS-1 indicates no blasts in a nontraumatic sample; CNS-2 indicates fewer than 5 white blood cells per microliter with blasts in a nontraumatic sample; CNS-3 indicates 5 or more white blood cells per microliter with blasts in a nontraumatic sample or the presence of cranial nerve palsy; and TLP indicates 10 or more red blood cells per microliter with or without blasts. group, CNS status, and treatment era are summarized in Table 1. In this trial, the correction of thrombocytopenia before intrathecal treatment, deep sedation during the procedure, and the practitioners most skilled at performing lumbar puncture were recommended. Statistical Analysis Differences between categorical variables were examined with Fisher s exact test or the chi-square test. The Kaplan-Meier method was used to estimate survival rates, with differences compared with the log-rank test. The duration of OS was defined as the time from diagnosis to the date of death. The duration of EFS was defined as the time from diagnosis to the date of failure (relapse, death, or the development of a second malignancy) or the last follow-up date for all patients who lacked an adverse event. Patients who did not achieve complete remission were considered to have an EFS of zero. Logistic regression analysis was used to estimate relative risk in the multivariate analysis. For patients who achieved complete remission, cumulative incidence functions of isolated CNS or any CNS relapse were estimated with the method of Kalbfleisch and Prentice. 12 An isolated CNS relapse was defined as one without simultaneous relapse at another site, and any CNS relapse was defined as CNS relapse accompanied or not by relapse in the bone marrow or any other extramedullary site. All reported P values were based on 2-sided tests, and they were considered statistically significant if they were less than.05. Data were analyzed with IBM SPSS software (release 21.0; IBM, Armonk, New York). RESULTS Altogether, 1366 patients were enrolled in the TPOG- ALL-2002 study. 9 Twelve patients in (era 1) and 7 patients in (era 2) were excluded because of an unknown CNS status. Thus, 903 patients in era 1 and 444 patients treated with delayed TIT and without CrRT in era 2 were included in this study for further analysis. The presenting features of the patients in the 2 eras were balanced. 9 In this study, the prevalence of patients with hyperdiploidy was relatively high and that of t(12;21) positivity was quite low among the patients tested (63% of the total patients; Table 2). There were no significant differences between the 2 eras in the rates of EFS (75.7% ± 1.4% vs 72.1% ± 2.4%; P =.260) 3
4 TABLE 2. Clinical and Biological Characteristics According to the CNS Status in 2 Treatment Eras Treatment Era (With Irradiation) (Delayed 1st TIT and Omission of Irradiation) Characteristic Total CNS-1 Non CNS-1 a P Total CNS-1 Non CNS-1 a P All, No. 903 c d Sex, No Male Female Lineage B T Age, median (IQR), y Age, No. 5.0 ( ) 5.0 ( ) 4.1 ( ) 5.6 ( ) 5.6 ( ) 6.0 ( ) <1 y < y y WBCs, median (IQR), 10 9 /L WBCs, No ( ) 14.3 ( ) 44.4 ( ) 17.3 ( ) 16.8 ( ) 43.1 ( ) /L < > /L Risk group, No. <.01 < Standard High Very high t(9;22), No. 550 e e Present Absent t(1;19), No. 550 e e Present Absent t(12;21), No. 550 e e Present Absent MLL-R, No. 550 e e Present Absent Hyperdiploidy, 550 e e No. f Present Absent Abbreviations: CNS, central nervous system; IQR, interquartile range; MLL-R, MLL gene rearrangement; TIT, triple intrathecal therapy; WBC, white blood cell. a Non CNS-1 indicates CNS-2, CNS-3, or traumatic lumbar puncture with blasts. b Comparison of non CNS-1 patients between the 2 eras. c Exclusion of 12 patients with an unknown CNS status. d Exclusion of 7 patients with an unknown CNS status. e Number of patients who were tested. f Fifty-one to sixty-eight chromosomes. P b 4
5 Treatment Outcomes of Childhood ALL/Yeh et al A B Figure 1. Treatment outcomes of era 1 ( with cranial irradiation) and era 2 ( with delayed first triple intrathecal therapy and no cranial irradiation): (A) 5-year overall survival and event-free survival in the 2 treatment eras and (B) cumulative incidence of any CNS relapse and isolated CNS relapse in the 2 treatment eras. The data are presented as means and standard errors. CNS indicates central nervous system. or OS (83.0% ± 1.3% vs 79.4% ± 2.1%; P =.069) or in the cumulative incidences of any CNS (6.3% ± 0.8% vs 5.4% ± 1.2%; P =.563) or isolated CNS relapse (4.0% ± 0.7% vs 4.1% ± 1.0%; P =.960; Fig. 1). There were also no significant differences in the cumulative incidence of relapse, isolated bone marrow relapse, or non-cns relapse between patients treated in the 2 treatment eras (Fig. 2). Clinical and Biological Features of Patients With a Non CNS-1 Status A total of 76 patients were classified as having a non CNS-1 status (i.e., CNS-2, CNS-3, or TLP with blasts) in era 1, and there were 28 in era 2. Their clinical and biological characteristics are summarized in Table 2. The clinical and biological characteristics did not differ significantly between non CNS-1 patients in the 2 treatment eras, and this suggests that delayed TIT did not select out higher risk patients with a non CNS-1 status. Among patients with non CNS-1 leukemia treated in era 1, the median age at diagnosis was 4.1 years (interquartile range [IQR], years), and 11 patients were infants. The median leukocyte count was /L (IQR, /L), with 26 patients having counts greater than /L. There were 68 patients with B-precursor ALL, and there were 8 patients with T-cell ALL. In comparison with the clinical features of CNS-1 patients, a younger age (<1 year), a higher 5
6 Figure 2. Cumulative incidence of relapse, isolated BM relapse, and non-cns relapse in treatment era 1 ( with cranial irradiation) and treatment era 2 ( with delayed first triple intrathecal therapy and no cranial irradiation). The data are presented as means and standard errors. BM indicates bone marrow; CNS, central nervous system. leukocyte count (> /L), an HR/VHR classification, and an MLL rearrangement showed a significant association with a non CNS-1 status; however, only an HR/VHR designation retained statistical significance in a multivariate analysis (odds ratio, 2.625; 95% confidence interval, ; P <.001). In era 2, the median age at diagnosis was 6.0 years (IQR, years), and 2 patients were infants. The median leukocyte count was /L (IQR, /L), with 9 patients having counts greater than /L. There were 22 patients with B-precursor ALL, and there were 6 patients with T-cell ALL. As in era 1, the risk classification of HR/VHR was the only significant predictor of a non CNS-1 status in the multivariate model (odds ratio, 2.861; 95% confidence interval, ; P =.012). Treatment Outcomes for Non CNS-1 Patients Treated in Different Eras The numbers of patients with CNS-2, CNS-3, and TLP with blasts were 35, 25, and 16, respectively, in era 1 and 19, 9, and 0, respectively, in era 2. Although there was no difference in the frequency of patients with CNS-2 or CNS-3 between the 2 eras (60 of 903 patients vs 28 of 444 patients; P =.810), the classification of TLP with blasts was completely eliminated after the first TIT treatment was delayed in era 2. The 5-year EFS and OS rates among non CNS-1 patients treated in era 1 were 52.3% ± 5.8% and 61.8% ± 5.7%, respectively. The cumulative risk estimates for any CNS or isolated CNS relapse were 17.3% ± 4.8% and 6.3% ± 3.1% at 5 years, respectively. The 5-year EFS for this group after modified treatment in era 2 was 62.9% ± 9.4%, whereas the OS was 77.9% ± 8.0%; the cumulative risk estimates for any CNS relapse and isolated CNS relapse were both 3.6% ± 3.5%. Importantly, these comparisons between treatment eras (Table 3 and Fig. 3) did not show any statistically significant differences that would indicate a loss of efficacy due to the delay in the first TIT treatment and the omission of CrRT altogether. Instead, the cumulative rates of CNS relapse were uniformly lower in era 2 than era 1 (Table 3), and the only relapse after treatment modification occurred 8 months after remission. DISCUSSION In this study, we show that modified CNS-directed therapy with delayed administration of the first TIT treatment and total omission of CrRT did not compromise the outcomes of treatment for childhood ALL, even when the analyses were limited to patients with a non CNS-1 status. Our results are in line with previous studies showing that CrRT can be successfully omitted for all risk groups of childhood ALL in the context of effective systemic chemotherapy and intrathecal therapy. 13,14 It should be noted that our results were obtained with a relatively high number of TIT treatments (14-19 doses in 6
7 Treatment Outcomes of Childhood ALL/Yeh et al TABLE 3. Treatment Outcomes According to the CNS Status in 2 Treatment Eras Non CNS-1 Status No. (%) a 5-y EFS, Mean ± SE, % 5-y OS, Mean ± SE, % 5-y Any CNS Relapse, Mean ± SE, % (No. of Relapses) 5-y Isolated CNS Relapse, Mean ± SE, % (No. of Relapses) Treatment Era 1: (With Irradiation) Total 76 (8.4) 52.3 ± ± ± 4.8 (11) 6.3 ± 3.1 (4) CNS-2 35 (3.9) 66.8 ± ± ± 5.5 (3) 0 CNS-3 25 (2.8) 41.8 ± ± ± 9.9 (5) 20.5 ± 9.5 (4) TLP with blasts 16 (1.8) b 37.5 ± ± ± 12.6 (3) 0 Treatment Era 2: (Delayed 1st TIT and Omission of Irradiation) Total 28 (6.3) 62.9 ± ± ± 3.5 (1) 3.6 ± 3.5 (1) CNS-2 19 (4.3) 62.0 ± ± ± 5.1 (1) 5.3 ± 5.1 (1) CNS-3 9 (2.0) 66.7 ± ± TLP with blasts 0 b ND ND ND ND Abbreviations: CNS, central nervous system; EFS, event-free survival; ND, not done; OS, overall survival; SE, standard error; TIT, triple intrathecal therapy; TLP, traumatic lumbar puncture. a Percentages are based on the total number of patients (903) in era 1. b Statistically significant between the 2 treatment eras. c Percentages are based on the total number of patients (444) in era 2. SR patients, doses in HR patients, and doses in VHR patients), 4 courses of high-dose methotrexate (at 2.5 g/m 2 in SR patients and at 5 g/m 2 in HR/VHR patients), and large cumulative doses of dexamethasone (1120 mg/m 2 in SR patients, 1620 mg/m 2 in HR patients, and 882 mg/m 2 in VHR patients). Vora et al 6 analyzed the impact of CrRT on clinical outcomes among patients treated in 10 major collaborative studies of childhood ALL with substantial differences in the proportions of patients receiving CrRT, which ranged from 0% to 33%. Their meta-analysis identified patients with CNS-3 at diagnosis as the only subgroup with a reduction in the rate of any or isolated CNS relapses after CrRT, but there were no significant differences in the cumulative risk of any adverse events or in survival between patients with a CNS-3 status treated with or without CrRT. They concluded that the use of prophylactic CrRT did not have an important impact on the risk of treatment outcomes in almost all subgroups of ALL treated with contemporary protocols. The reported rates of CNS-2 and CNS-3 leukemia in children have ranged from 5.4% to 32.2% and from 1.6% to 4.7%, respectively, 5,6 with EFS and OS rates for patients with CNS disease ranging from 43% to 86% and from 64% to 95%, respectively, depending on whether infants or patients with a CNS-2 status or TLP with blasts were enrolled. 5,6,8,13 28 In the TPOG-ALL-2002 study, the incidence rates for CNS-2 and CNS-3 involvement were similar to those cited previously and did not change significantly from one treatment era to the next. Treatment outcomes in patients with a CNS-2 or CNS-3 status were also comparable to results obtained in contemporary trials that adopted the same definition of CNS status. 8,14 17,24,28 In fact, in our study, non CNS-1 patients in era 2 tended to have better EFS and OS than those in era 1 (Fig. 3A), and this suggests that the delay in TIT actually could improve outcomes. In addition, the advances in supportive care, especially with the prophylactic use of antibiotics and antifungals, 29 the decrease in dropout rates, and the wide coverage of National Health Insurance in Taiwan also might have contributed to the trend of outcome improvements in era 2. Notably, the EFS of patients with a non CNS-1 status was inferior to that of CNS-1 patients only in era 1 (P <.001) and not in era 2 (P =.115). TLP with blasts has been reported to occur in 5.6% to 14.5% of patients with childhood ALL if the first puncture is performed at the time of diagnosis. 5,14,30 TLP contaminated with blasts has also been shown to be a risk factor for CNS relapse. 8 Several studies have reported EFS rates ranging from 56% to 81%. 5,8,14 17,28,31 Importantly, in our study, the modification of delaying the first TIT treatment eliminated the occurrence of TLP with blasts altogether. The other advantages of delaying the initial intrathecal therapy include the avoidance of sedation of patients with a mediastinal mass at diagnosis and the elimination of the potential toxicities of delayed clearance of methotrexate in patients with acute kidney injury because they are not exposed to methotrexate, which is a major component of intrathecal therapy. The outcomes of CNS involvement in ALL patients with a non CNS-1 status are not routinely reported. 7
8 A B Figure 3. Treatment outcomes of patients with a non CNS-1 status (CNS-2, CNS-3, or traumatic lumbar puncture with blasts) in era 1 ( with cranial irradiation) and era 2 ( with delayed first triple intrathecal therapy and no cranial irradiation): (A) 5-year overall survival and event-free survival in the 2 treatment eras and (B) cumulative incidence of any CNS relapse and isolated CNS relapse in the 2 treatment eras. The data are presented as means and standard errors. CNS indicates central nervous system. Pui and Howard 5 reviewed this issue and showed that the risk of any CNS relapse at 5 years ranges from 2.3% to 20.2% for CNS-2, from 10% to 33.3% for CNS-3, and from 8.0% to 9.1% for TLP with blasts. In a recent Children s Oncology Group study of patients with SR and HR B-cell ALL, the 5-year any CNS relapse rate was 5.6% for patients with a CNS-2 status and 5.1% for those with a CNS-3 status who received 18 Gy of CrRT; this was significantly higher than the 2.0% for patients with a CNS-1 status. 27 In the current study, the 5-year cumulative risk for any CNS relapse in non CNS-1 patients decreased from 17.3% in era 1 to 3.6% in era 2. Furthermore, the Mackay study in Taiwan 7 continued to enroll a total of 187 newly diagnosed patients between 1999 and All the lumbar puncture and TIT procedures were performed by the most skillful practitioners in our division. In this cohort, only a single infant had a CNS-2 status, and none had CNS-3 involvement or TLP with blasts. As of December 31, 2015, there were only 4 patients with any type of CNS relapse and 1 patient with an isolated CNS relapse. The 5-year EFS and OS rates and cumulative rates of any and isolated CNS relapse were 84.5% ± 2.7%, 91.8% ± 2.0%, 2.3% ± 2.1%, and 0.6% ± 0.6%, respectively (Fig. 4). No SR patients 8
9 Treatment Outcomes of Childhood ALL/Yeh et al Figure 4. Treatment outcomes of a single-institution study enrolling a total of 187 newly diagnosed patients between 1999 and 2012 at Mackay Memorial Hospital. The 5-year overall survival and event-free survival and the cumulative incidence of any CNS relapse and isolated CNS relapse are shown. The data are presented as means and standard errors. CNS indicates central nervous system. needed to be upgraded to HR because of a CNS-3 status or TLP with blasts. The advances in supportive care, especially the use of prophylactic antibiotics and antifungals, 29 and better compliance with the treatment protocol have additional positive impacts on the improvement of the treatment outcomes in this single-institution study. Altogether, these findings were pivotal in shaping the design of the nationwide TPOG-ALL-2002 study because they suggested the feasibility of a favorable outcome with a delayed first TIT injection, less intensive systemic chemotherapy, and uniform omission of CrRT, which could be expected to benefit patients. In conclusion, a delay of the first TIT procedure until the clearance of circulating blasts together with the complete omission of CrRT did not compromise either the survival or the control of CNS leukemia for children with ALL, including those with a non CNS-1 status. In the longer term, the omission of CrRT for all patients should lead to much lower rates of second cancers and cognitive deficits. FUNDING SUPPORT This work was supported by grants from Mackay Memorial Hospital, Taipei, Taiwan (MMH-E and MMH-E ), and the Ministry of Science and Technology, Taipei, Taiwan (MOST B MY3). CONFLICT OF INTEREST DISCLOSURES The authors made no disclosures. AUTHOR CONTRIBUTIONS Ting-Chi Yeh: Conceptualization, methodology, formal analysis, investigation, patient contribution, data checking, writing original draft, and writing review and editing. Der-Cherng Liang: Conceptualization, methodology, validation, formal analysis, investigation, patient contribution, writing original draft, writing review and editing, and supervision. Jen-Yin Hou: Methodology, formal analysis, patient contribution, data checking, writing original draft, and writing review and editing. Tang-Her Jaing: Patient contribution and writing review and editing. Dong-Tsamn Lin: Patient contribution and writing review and editing. Chao-Ping Yang: Patient contribution and writing review and editing. Ching-Tien Peng: Patient contribution and writing review and editing. Iou-Jih Hung: Patient contribution and writing review and editing. Kai-Hsin Lin: Patient contribution and writing review and editing. Chih-Cheng Hsiao: Patient contribution and writing review and editing. Shiann-Tarng Jou: Patient contribution and writing review and editing. Shyh-Shin Chiou: Patient contribution and writing review and editing. Jiann-Shiuh Chen: Patient contribution and writing review and editing. Shih-Chung Wang: Patient contribution and writing review and editing. Te-Kau Chang: Patient contribution and writing review and editing. Kang-Hsi Wu: Patient contribution and writing review and editing. Jiunn-Ming Sheen: Patient contribution and writing review and editing. Hsiu-Ju Yen: Patient contribution and writing review and editing. Shih-Hsiang Chen: Patient contribution and writing review 9
10 and editing. Meng-Yao Lu: Patient contribution and writing review and editing. Meng-Ju Li: Patient contribution and writing review and editing. Tai-Tsung Chang: Patient contribution and writing review and editing. Ting-Huan Huang: Patient contribution and writing review and editing. Yu-Hsiang Chang: Patient contribution and writing review and editing. Shu-Huey Chen: Patient contribution and writing review and editing. Yung-Li Yang: Patient contribution and writing review and editing. Hsiu-Hao Chang: Patient contribution and writing review and editing. Bow-Wen Chen: Patient contribution and writing review and editing. Pei-Chin Lin: Patient contribution and writing review and editing. Chao-Neng Cheng: Patient contribution and writing review and editing. Yu-Hua Chao: Patient contribution and writing review and editing. Shang-Hsien Yang: Patient contribution and writing review and editing. Yu-Mei Y. Chao: Writing review and editing. Hsi-Che Liu: Conceptualization, methodology, validation, formal analysis, investigation, patient contribution, data checking, writing original draft, writing review and editing, and visualization. REFERENCES 1. Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349: Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297: Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297: Waber DP, Turek J, Catania L, et al. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium protocol J Clin Oncol. 2007;25: Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9: Vora A, Andreano A, Pui CH, et al. Influence of cranial radiotherapy on outcome in children with acute lymphoblastic leukemia treated with contemporary therapy. J Clin Oncol. 2016;34: Liu HC, Yeh TC, Hou JY, et al. Triple intrathecal therapy alone with omission of cranial radiation in children with acute lymphoblastic leukemia. J Clin Oncol. 2014;32: Gajjar A, Harrison PL, Sandlund JT, et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood. 2000;96: Li MJ, Liu HC, Yen HJ, et al. Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation. Pediatr Blood Cancer. 2017;64: Liang DC, Yang CP, Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24: Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329: Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Hoboken, NJ: John Wiley & Sons Inc; Veerman AJ, Kamps WA, van den Berg H, et al. Dexamethasonebased therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 ( ). Lancet Oncol. 2009;10: Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360: Burger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21: te Loo DM, Kamps WA, van der Does-van den Berg A, van Wering ER, de Graaf SS. Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group. J Clin Oncol. 2006;24: Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111: Conter V, Arico M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24: Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE, COALL Study Group. Cooperative Study Group for Childhood Acute Lymphoblastic Leukaemia (COALL): long-term results of trials 82, 85, 89, 92 and 97. Leukemia. 2010;24: Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the Children s Cancer Group studies for childhood acute lymphoblastic leukemia : a Children s Oncology Group Report. Leukemia. 2010;24: Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to Leukemia. 2010;24: Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, Leukemia. 2010;24: Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to Leukemia. 2010;24: Pui CH, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24: Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24: Silverman LB, Stevenson KE, O Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia ( ). Leukemia. 2010;24: Winick N, Devidas M, Chen S, et al. Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children s Oncology Group. J Clin Oncol. 2017;35: Takahashi H, Kajiwara R, Kato M, et al. Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children s Cancer Study Group (TCCSG) study L Int J Hematol. 2018;108: Yeh TC, Liu HC, Hou JY, et al. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis. Cancer. 2014;120: Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92: Shaikh F, Voicu L, Tole S, et al. The risk of traumatic lumbar punctures in children with acute lymphoblastic leukaemia. Eur J Cancer. 2014;50:
11 Treatment Outcomes of Childhood ALL/Yeh et al Precis In this study, the delay of first triple intrathecal therapy until the clearance of circulating lymphoblasts and the total omission of cranial irradiation do not compromise survival or central nervous system control in childhood acute lymphoblastic leukemia, even when analyses are limited to patients with a"cns-1" is a common term to describe the CNS status in childhood acute lymphoblastic leukemia. I prefer to use "non-cns-1" or non-central nervous system (CNS)-1 status. 11
Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation
Original Article Page 1 of 9 Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation Wen-Han Kuo 1, Yu-Hsuan Chen
More informationProphylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010
Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Outline Epidemiology Risk-groups Background & Rationale
More informationSummary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5):
Rep Pract Oncol Radiother, 2007; 12(5): 283-288 Preliminary Communication Received: 2007.03.27 Accepted: 2007.07.24 Published: 2007.10.18 Authors Contribution: A Study Design B Data Collection C Statistical
More informationA lthough central nervous system (CNS) prophylaxis in patients with ALL has
Original Article Central nervous system relapse prophylaxis in acute lymphoblastic leukemia (ALL) intrathecal chemotherapy with and without cranial irradiation Ahmad Tamaddoni (MD) 1 Hassan Mahmodi Nesheli
More informationVOICES OF THE HIDDEN
VOICES OF THE HIDDEN I M P L E M E N TAT I O N O F T H E P E O P L E L I V I N G W I T H H I V S T I G M A I N D E X I N TA I WA N Yi-Chi Chiu 1, 2, Ting-Shu Wu 1, Yuan-Ti Lee 3, 4, Ning-Chi Wang 5, Wing-Wai
More informationConcomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
More informationPediatric Acute Leukemia: The Effect of Prognostic Factors on Clinical Outcomes at Phramongkutklao Hospital, Bangkok, Thailand
Pediatric Acute Leukemia: The Effect of Prognostic Factors on Clinical Outcomes at Phramongkutklao Hospital, Bangkok, Thailand Piya Rujkijyanont MD*, Suphathida Kaewinsang MD*, Chalinee Monsereenusorn
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationCorrelation of Sex and Remission of Acute Lymphoblastic Leukemia-L1 (ALL-L1) in Children
International Journal of Clinical and Experimental Medical Sciences 2015; 1(2): 11-15 Published online July 6, 2015 (http://www.sciencepublishinggroup.com/j/ijcems) doi: 10.11648/j.ijcems.20150102.12 Correlation
More informationJournal of Chinese Medicine. Vol.20, No.1, Vol.20, No.3,
163 Journal of Chinese Medicine Vol.20, No.1,2 1-96 Vol.20, No.3,4 97-162 ~ - 145 45-135 21 117 79-19 137-135 ~ - 137 65 87-65 - 145-65 - 153-79 - 153-87 47-137 - 65-87 - 47-145 - 145-47 - 19 164 153 HT7
More informationLOW INCIDENCE OF CNS RELAPSE WITH CRANIAL RADIOTHERAPY AND INTRATHECAL METHOTREXATE IN ACUTE LYMPHOBLASTIC LEUKEMIA
Original Articles LOW INCIDENCE OF CNS RELAPSE WITH CRANIAL RADIOTHERAPY AND INTRATHECAL METHOTREXATE IN ACUTE LYMPHOBLASTIC LEUKEMIA N.S. Raje, S.J. Vaidya, G. Kapoor, S.K. Pai, C.N. Nair, P.A. Kurkure,
More informationStandard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationPrognostic significance of leukopenia in childhood acute lymphoblastic leukemia
ONCOLOGY LETTERS 7: 1169-1174, 2014 Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia YUSUKE SHIOZAWA 1, JUNKO TAKITA 1,2, MOTOHIRO KATO 3, MANABU SOTOMATSU 4, KATSUYOSHI
More information2013 Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities ( 2017:27: (07)
116 2013 1 2 2 1 3 4 5 6 7 8 9 2 10 11 2 12 13 14 15 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 2025 2013 Guidelines for Prevention and Control of Tuberculosis In California Long Term Health Care Facilities
More informationTreating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
The new england journal of medicine original article Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation Ching-Hon Pui, M.D., Dario Campana, M.D., Ph.D., Deqing Pei, M.S., W. Paul
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Biondi A, Schrappe M, De Lorenzo P, et al.
More informationAcarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and. Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice
Acarbose Decreases the Rheumatoid Arthritis Risk of Diabetic Patients and Attenuates the Incidence and Severity of Collagen-induced Arthritis in Mice Authors: Chi-Chen Lin, Der-Yuan Chen, Ya-Hsuan Chao,
More informationA review of central nervous system leukaemia in paediatric acute myeloid leukaemia
EDITORIAL A review of central nervous system leukaemia in paediatric acute myeloid leukaemia Donna L. Johnston Division of Hematology/Oncology, Children s Hospital of Eastern Ontario, Ottawa, Ontario,
More informationEstimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants
ORIGINAL ARTICLE Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants Chien-Hung Chen, 1 Pei-Ming Yang, 1
More informationChang Gung Medical Journal
Vol. 32 No. 6 November-December 2009 Chang Gung Medical Journal CONTENTS IN BRIEF REVIEW ARTICLES 589 Mitochondrial Dysfunction and Biogenesis in the Pathogenesis of Parkinson s Disease Tsu-Kung Lin, MD,
More informationBalancing cure and long-term risks in acute lymphoblastic leukemia
INSIGHTS FROM PEDIATRIC HEMATOLOGIC MALIGNANCIES:FOCUS ON ACUTE LYMPHOCYTIC LEUKEMIA Balancing cure and long-term risks in acute lymphoblastic leukemia Lewis B. Silverman 1 1 Department of Pediatric Oncology,
More informationResults of LSA2-L, Therapy in Children with High-Risk Acute Lyrnphoblastic Leukemia and Non-Hodgkin's Lymphoma *
Haematology and Blood Transfusion Vol. 28 Modem Trends in Human Leukemia V Edited by Neth, Gallo, Greaves, Moore, Winkler @ Springer-Verlag Berlin Heidelberg 1983 Results of LSA2-L, Therapy in Children
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
V O L U M E 2 6 N U M B E R 1 8 J U N E 2 0 2 0 0 8 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationPediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08)
Pediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08) Department of Pediatric Hematology/Oncology King Fahd National Centre for Children s Cancer and Research King Faisal Specialist Hospital and
More informationThe probability of curing children with acute. brief report
brief report Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) Khadra
More informationChang Gung Medical Journal
Vol. 32 No. 5 September-October 2009 Chang Gung Medical Journal CONTENTS IN BRIEF REVIEW ARTICLES 471 C-reactive Protein and Malignancy: Clinico-pathological Association and Therapeutic Implication Chia-Siu
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationCharacteristics of Taiwanese patients of PNH in the international PNH registry
The Author(s) Thrombosis Journal 2016, 14(Suppl 1):39 DOI 10.1186/s12959-016-0094-0 RESEARCH Characteristics of Taiwanese patients of PNH in the international PNH registry Open Access Wen-Chien Chou 1,
More informationBiliary atresia (BA) is an inflammatory, progressive
Effects of the Infant Stool Color Card Screening Program on 5-Year Outcome of Biliary Atresia in Taiwan Tien-Hau Lien, 1 Mei-Hwei Chang, 1 Jia-Feng Wu, 1 Huey-Ling Chen, 1 Hung-Chang Lee, 2 An-Chyi Chen,
More informationAdult ALL: NILG experience
Adult ALL: NILG experience R Bassan USC Ematologia, Ospedali Riuniti, Bergamo SIE Interregionale, Padova 12 5 2011 Now and then Northern Italy Leukemia Group 2000-10 Prospective clinical trials 09/00 10/07
More informationCURRICULUM VITAE. Name: PoTsung Chen, Ph.D.
CURRICULUM VITAE Name: PoTsung Chen, Ph.D. #1 University Rd, Dept. of Architecture, NCKU Tainan, Taiwan, 701 Tel:886-6-252-1019 Fax:886-6-281-0380 Email:potsung@mail.ncku.edu.tw (1)Personal Information:
More informationΙL-8 and MCP-1 in children with acute lymphoblastic leukemia and potential correlation with neurotoxicity and thromboembolic phenomena
International Journal of Diseases and Disorders ISSN: 9-985 Vol. 1 (), pp. 55-58, November, 1. Available online at www.internationalscholarsjournals.org International Scholars Journals Full Length Research
More informationRisk Stratification in Childhood Leukemia
Risk Stratification in Childhood Leukemia Why is risk stratification important? Toxicities Deepa Bhojwani, MD May 11, 2018 To determine intensity of therapy - When to intensify therapy - When to de-intensify
More informationPhiladelphia chromosome-positive acute lymphoblastic leukemia in childhood
Review article DOI: 10.3345/kjp.2011.54.3.106 Korean J Pediatr 2011;54(3):106-110 Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood Hong Hoe Koo, M.D., Ph.D. Department of Pediatrics,
More informationTOP PAPERS FOR TAIWAN IN SOCIAL SCIENCES, GENERAL
頁 1 / 8 TOP PAPERS FOR TAIWAN IN Sorted by: Citations 1-20 (of 27) [ 1 2 ] Page 1 of 2 1 Citations: 406 THREE APPROACHES TO QUALITATIVE CONTENT ANALYSIS HSIEH HF; SHANNON SE QUAL HEALTH RES 15 (9): 1277-1288
More informationHEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN
UNIVERSAL HEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN MEI-HWEI CHANG, M.D., CHIEN-JEN CHEN, SC.D., MEI-SHU LAI, M.D., HSU-MEI HSU, M.P.H., TZEE-CHUNG WU,
More informationName: Shun-Te Huang. Tel: ext.2272
Name: Shun-Te Huang Email: shuntehuang@gmail.com Tel: 886-7-3121101 ext.2272 EDUCATION: Ph. D. 1979-1983 Department of Pediatric Dentistry, Graduate School of Dentistry, Osaka dental University. Japan
More informationIsolated Central Nervous System Relapse of Acute Lymphoblastic Leukemia
CASE REPORT Brain Tumor Res Treat 2014;2(2):114-118 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2014.2.2.114 Isolated Central Nervous System Relapse of Acute Lymphoblastic Leukemia
More informationControversies in Hematology: Case-Based Discussion. Acute leukemia in Adolescents and Young adults October 2018, Chiang Mai Thailand
Controversies in Hematology: Case-Based Discussion Acute leukemia in Adolescents and Young adults 25-26 October 2018, Chiang Mai Thailand Associate Prof. Adisak Tantiworawit, MD Division of Hematology,
More informationCurrent Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review
EXPERT OPINION Current Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review Chi-Kong Li Department of Pediatrics, Prince of Wales Hospital, The Chinese University
More informationSQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY IN THE ELDERLY
ORIGINAL ARTICLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY IN THE ELDERLY Yi-Shing Leu 1,2,3 *, Yi-Fang Chang 4, Jehn-Chuan Lee 1, Chung-Ji Liu 2,5,6, Hung-Tao Hsiao 7, Yu-Jen Chen 8, Hong-Wen Chen 8,9,
More informationOverdiagnosis in. Outline
Overdiagnosis in Mammography Screening Jean Ching-Yuan Fann, Huei-Shian Tsau, Chen-Yang Hsu, King-Jen Chang, Amy Ming-Fang Yen, Cheng-Ping Yu, Sam Li-Sheng Chen, Wen-Hung Kuo, László Tabár, Sherry Chiu,
More information1 Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland. 2 Childrens Cancer Research Unit, Karolinska Institute, Stockholm,
Pediatr Blood Cancer 2004;42:8 23 Outcome of Children With High-Risk Acute Lymphoblastic Leukemia (HR-ALL): Nordic Results on an Intensive Regimen With Restricted Central Nervous System Irradiation Ulla
More informationSupplementary Information. Statins Improve Long Term Patency of Arteriovenous Fistula for
Supplementary Information Statins Improve Long Term Patency of Arteriovenous Fistula for Hemodialysis Hao-Hsiang Chang MD, MSc 1,2, Yu-Kang Chang PhD 3, Chia-Wen Lu MD 1, Chi-Ting Huang 3, Chiang-Ting
More informationTreatment of Young Children With CNS-Positive Acute Lymphoblastic Leukemia Without Cranial Radiotherapy
Pediatr Blood Cancer 2015;62:1881 1885 Treatment of Young Children With CNS-Positive Acute Lymphoblastic Leukemia Without Cranial Radiotherapy Marta Wilejto, MD,* Giancarlo Di Giuseppe, BSc, Johann Hitzler,
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationChemotherapy of Breast Cancer
Japan - Taiwan Joint Symposium on Medical Oncology Session 7 Breast cancer journal homepage:www.cos.org.tw/web/index.asp Chemotherapy of Breast Cancer Mei-Ching Liu Department of Medicine, Koo Foundation
More informationIncidence and Risk of Alcohol Use Disorders by Age, Gender and Poverty Status: A Population-Based-10 Year Follow-Up Study
Incidence and Risk of Alcohol Use Disorders by Age, Gender and Poverty Status: A Population-Based-10 Year Chun-Te Lee 1,2, Chiu-Yueh Hsiao 3, Yi-Chyan Chen 4,5, Oswald Ndi Nfor 6, Jing-Yang Huang 6, Lee
More informationHow Do You Measure Success in ALL?: Assessment of MRD
How Do You Measure Success in ALL?: Assessment of MD Martin Schrappe, MD, PhD University Medical Center Schleswig-Holstein Christian-Albrechts-University Kiel, Germany Topics Current risk classification
More informationINTERFANT-06 INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA
INTERFANT-06 INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA Participating groups: DCOG (the Netherlands) BFM-G (Germany) CORS
More informationDecreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
ARTICLE Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study Mei-Hwei Chang, San-Lin You, Chien-Jen Chen, Chun-Jen Liu, Chuan-Mo Lee, Shi-Ming Lin, Heng-Cheng
More informationCHILDHOOD CANCER SURVIVAL STUDY CONCEPT PROPOSAL
Version: March 3, 2006 CHILDHOOD CANCER SURVIVAL STUDY CONCEPT PROPOSAL I- Title: Neurocognitive and Psychosocial Correlates of Adaptive Functioning in Survivors of Childhood Leukemia and Lymphoma. II-
More informationFactors influencing survival after relapse from acute lymphoblastic leukemia: a Children s Oncology Group study
(2008) 22, 2142 2150 & 2008 Macmillan Publishers Limited All rights reserved 0887-6924/08 $32.00 www.nature.com/leu ORIGINAL ARTICLE Factors influencing survival after relapse from acute lymphoblastic
More informationDetection of Leukemic Lymphoblasts in CSF Is Instrument-Dependent
Hematopathology / Detection of Lymphoblasts in CSF Detection of Leukemic Lymphoblasts in CSF Is Instrument-Dependent lison R. Huppmann, MD, 1 Susan R. Rheingold, MD, 2 L. Charles ailey, MD, 2 Marybeth
More informationRisk factors and mortality of adults with lung cancer admitted to the intensive care unit
Original Article Risk factors and mortality of adults with lung cancer admitted to the intensive care unit Chih-Cheng Lai 1#, Chung-Han Ho 2,3#, Chin-Ming Chen 4,5, Shyh-Ren Chiang 5,6, Chien-Ming Chao
More informationChang Gung Medical Journal
Vol. 34 No. 1 January-February 2011 Chang Gung Medical Journal CONTENTS IN BRIEF REVIEW ARTICLES 1 Surface Anthropometric Indices in Obesity-related Metabolic Diseases and Cancers Chao-Yang Yang, PhD;
More informationResearch Article Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults Protocols
Advances in Hematology, Article ID 697675, 7 pages http://dx.doi.org/10.1155/2014/697675 Research Article Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults Protocols
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationRelapsed acute lymphoblastic leukemia. Lymphoma Tumor Board. July 21, 2017
Relapsed acute lymphoblastic leukemia Lymphoma Tumor Board July 21, 2017 Diagnosis - Adult Acute Lymphoblastic Leukemia (ALL) Symptoms/signs include: Fever Increased risk of infection (especially bacterial
More informationIsolated Testicular Relapse in Acute Lymphoblastic Leukemia - Effective Treatment with the Modified CCG-112 Protocol
Original Article Isolated Testicular Relapse in Acute Lymphoblastic Leukemia - Effective Treatment with the Modified CCG-112 Protocol Goyal Shama, Bhagwat Roshni, Pai Suresh K, Kurkure Purna A, Nair Chandrika
More informationCurriculum Vitae. B. S. Department of Nutrition and Food Sciences
Name: Young, Guang-Huar Curriculum Vitae Address: 2F.-1, No.6, Ln. 144, Anle Rd., Yonghe Dist., New Taipei City 23455, Taiwan (R.O.C.) Tel: 886-2-29491565 E-mail: r6623612@ms24.hinet.net; youngguanghuar@gmail.com
More informationJPMA ( Journal Of Pakistan Medical Association) Vol 53, No.9,Sep Original Articles
JPMA ( Journal Of Pakistan Medical Association) Vol 53, No.9,Sep. 2003 Original Articles Outcome of Adult Acute Lymphoblastic Leukemia: a Single Center Experience M. Usman, I. Burney*, A. Nasim*, S. N.
More informationCHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL 1. Study title: Subsequent neoplasms among survivors of childhood cancer not previously treated with radiation 2. Working group and investigators:
More informationLONG-TERM FOLLOW-UP OF TREATMENT OF BURKTT'S LYMPHOMA -SINGLE INSTITUTION EXPERIENCE
LONG-TERM FOLLOW-UP OF TREATMENT OF BURKTT'S LYMPHOMA -SINGLE INSTITUTION EXPERIENCE 譚傳德, 劉美瑾, 陳博文, 吳茂青, 邱倫瑋, 陳鵬宇, 吳佳興, 李明媛, 曹美華, 黃玉儀 和信治癌中心醫院血液淋巴及幹細胞移植團隊 Tran-Der Tan* 1, Mei-Ching Liu1, Mau-Ching Wu1,
More informationChang Gung Medical Journal
Vol. 29 No. 5 September-October 2006 Chang Gung Medical Journal CONTENTS IN BRIEF FORUM 445 The Role of Metformin in the Treatment of Polycystic Ovary Syndrome (PCOS) Hsin-Shih Wang, MD, PhD REVIEW ARTICLE
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationImproved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Improved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant Jeong A Park 1,
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationClinical characteristics and prognosis of pediatric patients with B cell acute lymphoblastic leukemia relapse
ONCOLOGY LETTERS 16: 2929-2934, 2018 Clinical characteristics and prognosis of pediatric patients with B cell acute lymphoblastic leukemia relapse XIAOHONG ZHANG 1*, HAIXIA WU 2*, HONG FAN 3, BAIFANG SU
More informationPediatric Acute Lymphoblastic Leukemia. Highlights of ASH 2015
Pediatric Acute Lymphoblastic Leukemia Highlights of ASH 2015 Thai National Protocol Outcomes Outcome is very dependent on treatment Patient s compliance Treatment of ALL Induction Intensification Maintenance
More informationBiliary atresia (BA) is the most common lifethreatening. Universal Screening for Biliary Atresia Using an Infant Stool Color Card in Taiwan
AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Universal Screening for Biliary Atresia Using an Infant Stool Color Card in Taiwan Cheng-Hui Hsiao, 1 Mei-Hwei Chang, 2 Huey-Ling Chen, 2 Hung-Chang Lee, 3,4
More informationOrgan system-based integrated curriculum for 4 th -year medical students First semester
Organ system-based integrated curriculum for 4 th -year medical students First semester 2018-2019 Week 1 [ Introduction] 08:10-08:20 Integrated Curriculum Introduction of integrated Curriculum Shan-Chwen
More informationEfficacy of Extracorporeal Shock Wave Lithotripsy on the Treatment of Upper Urinary Tract Stones
38 ORIGINAL ARTICLE Efficacy of Extracorporeal Shock Wave Lithotripsy on the Treatment of Upper Urinary Tract Stones Tien-Huang Lin 1, Chao-Hsiang Chang 1,2, Chin-Chung Yeh 1,2, Wu-Nan Chen 3, Shi-San
More informationHepatitis B virus (HBV) infection is an important. Brief Communication
Brief Communication Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination Yen-Hsuan Ni, MD, PhD; Mei-Hwei Chang, MD; Li-Min Huang,
More informationSupplementary Text. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry
Supplementary Text Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry Takaya Moriyama a, Yung-Li Yang b, Rina Nishii a, c, Hany Ariffin
More informationChang Gung Medical Journal
Vol. 33 No. 2 March-April 2010 Chang Gung Medical Journal CONTENTS IN BRIEF REVIEW ARTICLES 115 The Role of Insulin Receptor Signaling in Synaptic Plasticity and Cognitive Function Chiung-Chun Huang, PhD;
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationWith contemporary treatment, 80% to 90% of children with acute
157 Prognostic Factors and Outcome of Recurrence in Childhood Acute Myeloid Leukemia Jeffrey E. Rubnitz, MD, PhD 1,2 Bassem I. Razzouk, MD 1,2 Shelly Lensing, MS 3 Stanley Pounds, PhD 3 Ching-Hon Pui,
More informationCHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in Survivors of Childhood Leukemia with Down Syndrome Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Long-Term Morbidity in of Childhood Leukemia with Down Syndrome Analysis Concept Proposal Working Group and Investigators Genetics Working Group & Chronic Disease Working
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More informationPlenary Lecture March 21. [OP] Opening Ceremony 08:30-09:30 March 21 (Saturday) [Rm 201] [PL01] TSA Lecture 09:30-10:00 March 21 (Saturday) [Rm 201]
Scientific Program Plenary Lecture March [OP] Opening Ceremony 08:30-09:30 March (Saturday) [Rm 0] [PL0] TSA Lecture 09:30-0:00 March (Saturday) [Rm 0] Chairpersons: Shen-Long Howng, Shoei-Shen Wang 09:30-0:00
More informationCURRICULUM VITAE China Medical College, College of Medicine, Taichung, Taiwan, R.O.C.
CURRICULUM VITAE NAME: Huang, Chung-Ming OFFICE ADDRESS: China Medical University Hospital, No. 2, Yuh-Der Road, Taichung, Taiwan, R.O.C., 北 路 2 EDUCATION: 1978-1985 China Medical College, College of Medicine,
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More information1. Study Title. Exercise and Late Mortality in 5-Year Survivors of Childhood Cancer: a Report from the Childhood Cancer Survivor Study.
CCSS Analysis Concept Proposal Exercise, Mortality, & Childhood Cancer 1 1. Study Title. Exercise and Late Mortality in 5-Year Survivors of Childhood Cancer: a Report from the Childhood Cancer Survivor
More informationThe Younger Patients Have More Better Prognosis in Limited Disease Small Cell Lung Cancer
ORIGINAL ARTICLE http://dx.doi.org/10.4046/trd.2016.79.4.274 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2016;79:274-281 The Younger Patients Have More Better Prognosis in Limited Disease
More informationMRD in ALL: Correct interpretation in clinical practice. Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh
MRD in ALL: Correct interpretation in clinical practice Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh Minimal residual disease Subclinical level of residual leukemia Below
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationby S.M. Ng, H.P. Lin, W.A. Arif n, A.K. Zainab, S.K. Lam and L.L. Chan Department of Paediatrics, University Hospital, Kuala Lumpur 59100, Malaysia
Age, Sex, Haemoglobin Level, and White Cell Count at Diagnosis are Important Prognostic Factors in Children with Acute Lymphoblastic Leukemia Treated with BFM-type Protocol by S.M. Ng, H.P. Lin, W.A. Arif
More informationCONVENTIONAL VS. INDIVIDUALIZED CHEMOTHERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
CONVENTIONAL COMPARED WITH INDIVIDUALIZED CHEMOTHERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA WILLIAM E. EVANS, PHARM.D., MARY V. RELLING, PHARM.D., JOHN H. RODMAN, PHARM.D., WILLIAM R. CROM, PHARM.D.,
More informationCitation for published version (APA): van Dijk, I. W. E. M. (2014). Radiation-associated adverse events after childhood cancer
UvA-DARE (Digital Academic Repository) Radiation-associated adverse events after childhood cancer van Dijk, Irma Link to publication Citation for published version (APA): van Dijk, I. W. E. M. (214). Radiation-associated
More informationH Schroeder 1, G Gustafsson 2, UM Saarinen-Pihkala 3, A Glomstein 4, G Jonmundsson 5, K Nysom 6, O Ringdén 7 and L Mellander 8.
Bone Marrow Transplantation, (1999) 23, 555 560 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Allogeneic bone marrow transplantation in second remission
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationComplications of varicella infection in children in southern Taiwan
Varicella J Microbiol infection Immunol in children Infect 2006;39:402-407 Complications of varicella infection in children in southern Taiwan Chia-Yu Chi 1,2, Shih-Min Wang 3, Hui-Chen Lin 2, Ching-Chuan
More informationHepatocellular carcinoma (HCC) is still one of the. Evaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan
HEPATOBILIARY MALIGNANCIES Evaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan Yen-Po Yeh, 1 Tsung-Hui Hu, 2 Po-Yuan Cho, 3 Hsiu-Hsi Chen, 4 Amy Ming-Fang Yen,
More informationTargeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD
Targeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD Harvard/Dana-Farber Cancer Institute Boston, MA Disclosures for Daniel J. DeAngelo, MD, PhD Royalty Receipt of intellectual property/ Patent
More informationIsolated Eye Relapse of Acute Lymphocy tic Leukemia during Intensification Therapy with Vincristine and Prednisolone
Jpn. J. Pediatr. Hematol. 2: 406-410, 1988 Case Report Isolated Eye Relapse of Acute Lymphocy tic Leukemia during Intensification Therapy with Vincristine and Prednisolone Fumio BEssHo,*1 Hiroshi KINUMAKI,*2
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More information